Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this research study is to determine whether hormonal therapies used early in the
course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen
(PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This
study will measure PSMA levels using standard PET/CT scans and participants will receive
standard-of-care androgen receptor antagonist monotherapy.
The names of the treatment interventions involved in this study are:
- Androgen receptor antagonist monotherapy.
- PSMA PET/CT scan
It is expected that about 15 people will take part in this research study.
Participation in this research study is expected to last about 4 weeks.